In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

This was a single-center, retrospective analysis of persistence on droxidopa for the management of orthostatic hypotension in adults patients. This study also evaluated adherence, patient-reported adverse events and falls as well as healthcare resource utilization.

This study of patients with RMS and ≥3 fills of DMT from a health-system specialty pharmacy evaluated DMT persistence. The probability of remaining persistent for 3 years was 0.51. Non-persistent patients mostly switched to a new DMT (39%), discontinued the DMT (26%) discontinued, or transferred care to a new specialty pharmacy or provider (27%). Specialty pharmacists played a key role in DMT transitions and initiated 7% of DMT discontinuations and 36% of DMT switches.

Vanderbilt Specialty Pharmacy (VSP) embeds pharmacists within an outpatient MS clinic to provide medication management and address barriers to adherence. We found an average adherence rate of 94% as measured by proportion of days covered (PDC), with 89% of all VSP patients achieving the industry standard of 80% PDC. Additionally, results indicate that ensuring financial assistance and low out-of-pocket costs are associated with high adherence to DMT within an integrated specialty clinic.

This study evaluated medication access rates in patients prescribed a PCSK9 inhibitor at a healthcare system with integrated specialty pharmacy services. Overall, 96% of prescriptions resulted in access to a PCSK9 inhibitor, with a median time to approval of 8 days. This high level of access supports this model as a best practice for prescribing PCSK9 inhibitor therapy.

This study evaluates PCSK9i persistence at 2, 12 and 24 months after initiation of therapy, reasons for non-persistence and percent change in LDL.

This study assessed patient-reported outcomes in patients prescribed specialty medications by an IBD clinic at a health system and dispensed by an integrated specialty pharmacy. A total of 515 MRQs were completed (median of 3 per patient; IQR 2, 3) during the study period. There were 2 reports of adverse effects and 11 reports of missing one or more medication doses. Medication effectiveness was rated as “excellent” in 13% (n=69) and “good” in 84% (n=433) of MRQ responses.

This study evaluated adherence rates and health outcomes across three academic centers with integrated specialty pharmacies. Centers with specialty pharmaies had high medicaiton possession ratio (MPR). Self-injectable biologic therapy non-adherence was associated with higher likelihood of emergency department visits and hospitalizations.

This study evaluated the impact of delayed insurance approval on outcomes in patients prescribed alternate doses of biologic therapy for the treatment of IBD. Researchers found that longer time to insurance approval of a higher biologic dosing regimen was associated with an increase in C-reactive protein, an inflammatory marker, in at least 45 days after the decision to escalate dose, suggesting the longer time to approval, the less likely to see an improvement in C-reactive protein.

The objective of this study was to evaluate if medication non-adherence is associated with increased healthcare resource utilization. In patients with moderate-to-severe IBD on self-injectable biologic medication, non-adherence (MPR 0.86) is associated with increased risk of hospitalization and emergency department visits.